132 related articles for article (PubMed ID: 16800244)
1. Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival.
Oksefjell H; Sandstad B; Trope C
Eur J Gynaecol Oncol; 2006; 27(3):209-14. PubMed ID: 16800244
[TBL] [Abstract][Full Text] [Related]
2. Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001.
Oksefjell H; Sandstad B; Tropé C
Eur J Gynaecol Oncol; 2007; 28(4):256-62. PubMed ID: 17713088
[TBL] [Abstract][Full Text] [Related]
3. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
4. Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer.
Grabowski JP; Harter P; Hils R; Lorenz D; Kaub C; Barinoff J; Heitz F; Traut A; du Bois A
Gynecol Oncol; 2012 Jul; 126(1):54-7. PubMed ID: 22472462
[TBL] [Abstract][Full Text] [Related]
5. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
Tropé CG; Elstrand MB; Sandstad B; Davidson B; Oksefjell H
Eur J Cancer; 2012 Sep; 48(14):2146-54. PubMed ID: 22382201
[TBL] [Abstract][Full Text] [Related]
7. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer.
Song N; Gao Y
Int J Gynecol Cancer; 2019 May; 29(4):761-767. PubMed ID: 30850437
[TBL] [Abstract][Full Text] [Related]
9. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
10. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
[TBL] [Abstract][Full Text] [Related]
11. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
12. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark.
Soegaard Andersen E; Knudsen A; Svarrer T; Lund B; Nielsen K; Grove A; Tetsche M
Gynecol Oncol; 2005 Dec; 99(3):552-6. PubMed ID: 16150480
[TBL] [Abstract][Full Text] [Related]
13. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
14. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
[TBL] [Abstract][Full Text] [Related]
16. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
Sørensen SM; Schnack TH; Høgdall C
Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
[TBL] [Abstract][Full Text] [Related]
17. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
18. Advanced epithelial ovarian carcinoma: long-term survival experience at the community hospital.
Unzelman RF
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 1):1663-71; discussion 1671-2. PubMed ID: 1615973
[TBL] [Abstract][Full Text] [Related]
19. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
Stoeckle E; Bourdarias L; Guyon F; Croce S; Brouste V; Thomas L; Floquet A
Ann Surg Oncol; 2014 Feb; 21(2):629-36. PubMed ID: 24052318
[TBL] [Abstract][Full Text] [Related]
20. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ
Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
